Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
INCHEON, Korea, April 05, 2024 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company’s proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda [...]